Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

BioNTech and Bristol Myers Squibb announced interim results from the ROSETTA Lung-02 Phase 2/3 study showing that their bispecific PD-L1xVEGF-A immunomodulator candidate Pumitamig demonstrated encouraging anti-tumor activity in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The drug showed confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous NSCLC subtypes at the lower dose, with consistent efficacy across all PD-L1 expression levels. The companies are advancing a comprehensive global Phase 3 development program with multiple ongoing trials.